Cargando…
Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
OBJECTIVE: Vesicular monoamine transporter-2 (VMAT2) inhibitors have been proven to be effective for the treatment of tardive dyskinesia and their use is likely to increase. The evidence base of published clinical reports was reviewed to evaluate the possible risk of neuroleptic malignant syndrome (...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean College of Neuropsychopharmacology
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242105/ https://www.ncbi.nlm.nih.gov/pubmed/32329312 http://dx.doi.org/10.9758/cpn.2020.18.2.322 |